UB Paderborn / Katalog / Suche / in CDI

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer

Frontiers in oncology, 2022-10, Vol.12, p.1022542-1022542

2022

Volltextzugriff (PDF)

Reply to Y. Wang et al and Q. Sui et al

Journal of clinical oncology, 2023-07, Vol.41 (21), p.3763-3764

2023

Volltextzugriff (PDF)

RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes

JCI insight, 2022-02, Vol.7 (3)

2022

Volltextzugriff (PDF)

Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

NPJ breast cancer, 2022-03, Vol.8 (1), p.31-31, Article 31

2022

Volltextzugriff (PDF)

Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer

Journal of clinical oncology, 2019-12, Vol.37 (35), p.3340-3349

2019

Volltextzugriff (PDF)

Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer

Journal of clinical oncology, 2023-03, Vol.41 (8), p.1533-1540

2023

Volltextzugriff (PDF)

Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

NPJ breast cancer, 2022-04, Vol.8 (1), p.54-54, Article 54

2022

Volltextzugriff (PDF)

Reply to V. Nardone et al

Journal of clinical oncology, 2023-08, Vol.41 (23), p.3959-3960

2023

Volltextzugriff (PDF)

ARe we there yet? Understanding androgen receptor signaling in breast cancer

NPJ breast cancer, 2020-09, Vol.6 (1), p.47-47, Article 47

2020

Volltextzugriff (PDF)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial

Journal of clinical oncology, 2023-04, Vol.41 (10), p.1841-1848

2023

Volltextzugriff (PDF)

Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers

Clinical cancer research, 2020-12, Vol.26 (24), p.6568-6580

2020

Volltextzugriff (PDF)

Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial

Clinical cancer research, 2023-05, Vol.29 (9), p.1783-1793

2023

Volltextzugriff (PDF)

Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy

Clinical cancer research, 2020-01, Vol.26 (1), p.171-182

2020

Volltextzugriff (PDF)

Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer

British journal of cancer, 2022-09, Vol.127 (5), p.927-936

2022

Volltextzugriff (PDF)

Inhibition of the p38 Kinase Suppresses the Proliferation of Human ER-Negative Breast Cancer Cells

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (23), p.8853-8861

2009

Volltextzugriff (PDF)

Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma

Neuro-oncology (Charlottesville, Va.), 2019-09, Vol.21 (9), p.1141-1149

2019

Volltextzugriff (PDF)

Bcl-xL inhibition radiosensitizes PIK3CA/PTEN wild-type triple negative breast cancers with low Mcl-1 expression

Cancer research communications, 2022-07, Vol.2 (7), p.679-693

2022

Volltextzugriff (PDF)

The radiosensitizing effects of monopolar spindle kinase I in syngeneic models of triple negative breast cancer and its implications on the tumor immune microenvironment

The Journal of immunology (1950), 2023-05, Vol.210 (1_Supplement), p.245-245.06

2023

Volltextzugriff (PDF)

Abstract 1386: The role of MDM2 inhibition in the radiosensitization of ER+ breast cancers

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1386-1386

2021

Volltextzugriff (PDF)

Abstract 1952: CDK4/6 inhibition radiosensitizes RB1 wild type triple negative breast cancers through impaired homologous recombination

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1952-1952

2021

Volltextzugriff (PDF)

Abstract 737: Estrogen receptor inhibition with tamoxifen mediates radiosensitization of ER+ breast cancer models

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.737-737

2021

Volltextzugriff (PDF)

Abstract PD9-06: Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.PD9-06-PD9-06

2022

Volltextzugriff (PDF)

Abstract P4-02-04: Endocrine therapy treatment radiosensitizes estrogen receptor-positive breast cancers

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.P4-P4-02-04

2022

Volltextzugriff (PDF)

Abstract 6270: A radiosensitizer screen identifies a novel role for MDM2 inhibition in the radiosensitization of ER+ breast cancers in a p53 dependent manner

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.6270-6270

2020

Volltextzugriff (PDF)

Abstract 1943: Radiosensitization of PIK3CA wild type triple negative breast cancers with Bcl-family inhibition

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.1943-1943

2021

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer

Reply to Y. Wang et al and Q. Sui et al

RB expression confers sensitivity to CDK4/6 inhibitor-mediated radiosensitization across breast cancer subtypes

Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer

Development and Validation of a Genomic Profile for the Omission of Local Adjuvant Radiation in Breast Cancer

Publisher Correction: Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models

Reply to V. Nardone et al

ARe we there yet? Understanding androgen receptor signaling in breast cancer

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial

Short-term CDK4/6 Inhibition Radiosensitizes Estrogen Receptor-Positive Breast Cancers

Integrating Tumor-Intrinsic and Immunologic Factors to Identify Immunogenic Breast Cancers from a Low-Risk Cohort: Results from the Randomized SweBCG91RT Trial

Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy

Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer

Inhibition of the p38 Kinase Suppresses the Proliferation of Human ER-Negative Breast Cancer Cells

Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma

Bcl-xL inhibition radiosensitizes PIK3CA/PTEN wild-type triple negative breast cancers with low Mcl-1 expression

The radiosensitizing effects of monopolar spindle kinase I in syngeneic models of triple negative breast cancer and its implications on the tumor immune microenvironment

Abstract 1386: The role of MDM2 inhibition in the radiosensitization of ER+ breast cancers

Abstract 1952: CDK4/6 inhibition radiosensitizes RB1 wild type triple negative breast cancers through impaired homologous recombination

Abstract 737: Estrogen receptor inhibition with tamoxifen mediates radiosensitization of ER+ breast cancer models

Abstract PD9-06: Evaluation of the predicted sensitivity to endocrine therapy (SET2,3 index) and the 21-gene Breast Recurrence Score® assay in node-positive postmenopausal breast cancer: Results from an analysis in the SWOG S8814 trial

Abstract P4-02-04: Endocrine therapy treatment radiosensitizes estrogen receptor-positive breast cancers

Abstract 6270: A radiosensitizer screen identifies a novel role for MDM2 inhibition in the radiosensitization of ER+ breast cancers in a p53 dependent manner

Abstract 1943: Radiosensitization of PIK3CA wild type triple negative breast cancers with Bcl-family inhibition

Aktive Filter

Suchergebnisse filtern